Samsung Bioepis Co., Ltd. vs. Alexion Pharmaceuticals, Inc. et al.

Explore the PTAB proceeding IPR2023-01070 filed by Samsung Bioepis Co., Ltd. on 2023-06-16. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Proceeding Overview

Proceeding Number

IPR2023-01070

Filing Date

2023-06-16

Accorded Filing Date

2023-06-16

Institution Decision Date

2023-12-19

Last Modified Date

2024-09-04

Proceeding Type

IPR

Termination Date

2024-09-04

Trial Status

Terminated-Settled

Parties & Counsel

Petitioner

Samsung Bioepis Co., Ltd.

Represented By

Rhyu, Michelleet al

Patent Owner / Respondent

Alexion Pharmaceuticals, Inc. et al.

Represented By

Flattmann, Geraldet al

Tribunal & Venue

Tribunal

Patent Trial and Appeal Board (USPTO)

Technology Center

TC 1600 - Biotechnology & Organic Chemistry

Patent Information

1 Patent Involved

Respondent Application Number 16804567

Respondent Patent Number 10703809

External Links

Espacenet

Google Patents

Respondent Inventor Leonard BELL et al

Respondent Tech Center TC 1600 - Biotechnology & Organic Chemistry

Address and Attorney/Agent Information

21 Registered Practitioners

Power of Attorney & Correspondence

Firm / Entity Name Nelson Mullins Riley & Scarborough LLP/Alexion

Customer Number 133485

Address ONE FINANCIAL CENTER, SUITE 3500, Boston, MA, 02111, UNITED STATES

Attorney / Agent Information

Reg #	Name	Phone
32343	Mark Dukes	803-255-9381
35218	Craig Killen	704-417-3127
35561	Neil Jones	864-250-2260
37320	Cynthia Kanik	617-202-4623
38220	Anthony Laurentano	617-202-4024
38872	Jane Remillard	617-202-4628
41302	Susan Jackson	704-417-3126
41710	Jeanne Di Giorgio	617-227-7400
42765	Jason Kraus	612-464-7549
55638	Todd Spalding	475-230-3372
56508	Nichole Hayden	864-250-2292
58468	Michael Yamauchi	203-699-7334
60760	Jill Gorny Sloper	617-994-0869
63014	Ashley Summer	864-250-2214
64678	Patrick Kartes	704-417-3036
65111	Rebecca Dise	312-616-5600
66617	Robert Mcwilliams Jr.	803-255-9380
67326	Christopher Frank	206-342-6255
72885	Sagun Kc	617-535-3991
76054	Jonathan Todd	803-206-3945
76221	Wing-Yeung Lau	857-338-8374

Proceeding Documents

185

Termination Decision: Post-DI Settlement TERMINATE

2024-09-04 FILING PARTY: BOARD

Download

Joint Motion to Terminate MOTION

2024-08-30 FILING PARTY: PATENT OWNER

Download

Joint Motion to Treat Settlement Agreement as Confidential MOTION

2024-08-30 FILING PARTY: PATENT OWNER

Download

ORDER Setting Oral Argument ORDER

2024-08-26 FILING PARTY: BOARD

Download

Petitioner's Request for Oral Hearing OTHER

2024-08-07 FILING PARTY: PETITIONER

Download

Samsung Bioepis Co., Ltd. vs. Alexion Pharmaceuticals, Inc. et al.

Proceeding Overview

Parties & Counsel

Petitioner

Samsung Bioepis Co., Ltd.

Represented By

Patent Owner / Respondent

Alexion Pharmaceuticals, Inc. et al.

Represented By

Tribunal & Venue

Patent Information

Address and Attorney/Agent Information

Power of Attorney & Correspondence

Attorney / Agent Information

Proceeding Documents

Termination Decision: Post-DI Settlement TERMINATE

Joint Motion to Terminate MOTION

Joint Motion to Treat Settlement Agreement as Confidential MOTION

ORDER Setting Oral Argument ORDER

Petitioner's Request for Oral Hearing OTHER

Patent Owner's Request for Oral Argument OTHER

2108 - 2024.07.16 Jeffrey Ravetch Deposition Transcript (FULL) Exhibit

Patent Owner's Updated Exhibit List NOTICE

Patent Owner's Sur-Reply OTHER

Notice of Deposition of J. Ravetch, M.D., Ph.D. NOTICE

SECOND MODIFIED SCHEDULING ORDER 37 C.F.R. § 42.5(c) ORDER

Exhibit 3005 Exhibit

Stipulation Modifying Due Dates OTHER

Petitioner's Reply ISO Petition REPLYTOOPP

Deposition of Arturo Casadevall, January 24, 2020 Exhibit

Petitioner's Updated Exhibit List NOTICE

Reply Declaration of Jeffrey V. Ravetch, M.D., Ph.D. Exhibit

Joint Stipulation Modifying Due Dates OTHER

2023 - Arturo Casadevall MD PhD CV Exhibit

2036 - Lo 2004 Exhibit

2082 - Frokjaer Exhibit

2088 - Amgen Biosimilar Pipeline Exhibit

2037 - Welt 2003 Exhibit

2090 - Samsung Bisolimilar Pipeline Exhibit

2049 - HemeOnc Today Exhibit

2075 - GenScript Final Report Exhibit

2089 - Generium Elizaria Exhibit

2031 - Janeway Appx 2005 Exhibit

2033 - Kim 2005 Exhibit

2054 - Alexion Press Release 9-20-2006 Exhibit

2083 - Rosenberg 2006 Exhibit

2050 - Fatimah 2016 Exhibit

2104 - 2024.02.23 Jeffrey Ravetch Deposition Transcript (FULL) Exhibit

2091 - Harlowe and Lane 1988 Exhibit

2047 - McClean 2005 Exhibit

2038 - Haller 2008 Exhibit

2030 - Alexion Press Release 3-16-2007 Exhibit

2084 - ICH Topic Q5C Exhibit

2006 - Dmytrijuk Exhibit

2035 - Shepherd Appx 2000 Exhibit

2040 - Torres 2005 Exhibit

2079 - Chang 2002 Exhibit

2028 - Hill 2007 Exhibit

2086 - Stebbings 2013 Exhibit

2085 - Q1AR2 Stability Testing Guidance Exhibit

2105 - Declaration of A. Casadevall (for POR) FINAL [809] Exhibit

2034 - Hwang 2005 Exhibit

2080 - Wang 1999 Exhibit

2025 - CV Bernhardt Trout 504 Exhibit

2042 - Mathiew 2004 Exhibit

2045 - 2007 USP Dictionary of USAN and Int'l Drug Names Exhibit

2053 - Soliris Current Label (06-2019 Label) Exhibit

2081 - Hermeling 2004 Exhibit

2051 - Foote 1992 Exhibit

2039 - Torres 2007 PLOS Article Exhibit

2029 - 1997 FDA Pts to Consider MAbs Exhibit

2055 - Alexion Press Release 9-26-2006 Exhibit

2044 - Chadd 2001 Exhibit

2107 - Declaration for B. Trout (for POR) FINAL [809] Exhibit

2043 - Andersen 2004 Exhibit

2014 - Greenspan Exhibit

Patent Owner Response RESPONSE

2046 - 1997 INN Naming Guidelines Exhibit

2052 - Xiang 1995 Exhibit

2106 - 2024.02.20 Cindy Ippoliti Deposition Transcript (FULL) Exhibit